Pharma BD Deal Intelligence

Royalty Pharma / Zealand Pharma A/S

2026 · Asset Purchase · $100M · Complete

Royalty Pharma agreed to pay Zealand Pharma USD 100 million for Zealand's economic interests in rusfertide (PTG-300), a potential first-in-class hepcidin mimetic for polycythemia vera, comprising rights to a 1% royalty on potential future global net sales plus regulatory and commercial milestones. Payment is staged: USD 50 million on closing and USD 50 million on the first anniversary of closing. Royalty Pharma retains a 0.75% royalty on annual global net sales above USD 1.5 billion while Zealand retains 0.25% above that threshold. The purchase and sale agreement closed on August 12, 2026. Zealand framed the transaction as monetizing a non-core royalty entitlement to redeploy capital to its strategic priorities.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Royalty Pharma deals